| Popis: |
Cynthia Matossian,1 William Trattler,2 Jennifer Loh3 1Matossian Eye Associates, Pennington, NJ, USA; 2Center for Excellence in Eye Care, Miami, FL, USA; 3Loh Ophthalmology Associates, Miami, FL, USACorrespondence: Cynthia MatossianMatossian Eye Associates, 2 Capital Way, Ste 326, Pennington, NJ, 08534, USATel +1 215-230-9200Email cmatossian@cmassociatesllc.netPurpose: To evaluate the efficacy of topical cyclosporine 0.1% in chondroitin sulfate emulsion for the treatment of dry eye.Methods: This retrospective multicenter study included 100 eyes of 50 dry eye patients aged ≥ 18 years, with preoperative ocular surface disease index (OSDI) score > 12 or corneal staining grade > 1 (in either eye) who underwent dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate emulsion (Klarity-C, ImprimisRx) for 3 months. Postoperative evaluation included comparison of the changes in OSDI score and corneal staining grade after 3 months of treatment from baseline.Results: From baseline to 3 months, a statistically significant improvement in mean OSDI scores (38.19 vs 24.18, p < 0.001) as well as mean corneal staining grade (3.62 vs 2.20, p < 0.001) was observed. The proportion of subjects with severe dry eye decreased from 62% to 20% and more than one-third (34%) of patients were in the normal OSDI range. The percentage of eyes with corneal staining grade of 2 or 3 decreased from 21% (baseline) to 8% at 3 months; 50% of the eyes had corneal staining grade of 0. The treatment was found to be safe with no adverse events observed in the study.Conclusion: Dry eye treatment with twice daily cyclosporine 0.1% in chondroitin sulfate emulsion was found to be safe and effective in reducing signs and symptoms of dry eye.Keywords: dry eye treatment, dry eye disease, cyclosporine 0.1%, Klarity-C, immunosuppressive agent DED |
